Interrupting transmission of genital herpes.
Griffiths
P D
PD
D015075:2-Aminopurine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D000212:Acyclovir / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use*; D017280:Condoms; D018849:Controlled Clinical Trials as Topic; D000077595:Famciclovir; D005260:Female; D006558:Herpes Genitalis / Q000453:epidemiology / Q000517:prevention & control / Q000635:transmission*; D022301:Herpes Simplex Virus Vaccines / Q000627:therapeutic use; D018258:Herpesvirus 2, Human / Q000276:immunology / Q000302:isolation & purification; D006801:Humans; D008297:Male; D021841:Safe Sex; D012736:Sex Education; D000077483:Valacyclovir; D014633:Valine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use
D000998:Antiviral Agents; D022301:Herpes Simplex Virus Vaccines; D015075:2-Aminopurine; D014633:Valine; D000077483:Valacyclovir; D000077595:Famciclovir; D000212:Acyclovir